BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 31311404)

  • 1. MDM2 inhibitor RG7388 potently inhibits tumors by activating p53 pathway in nasopharyngeal carcinoma.
    Fan X; Wang Y; Song J; Wu H; Yang M; Lu L; Weng X; Liu L; Nie G
    Cancer Biol Ther; 2019; 20(10):1328-1336. PubMed ID: 31311404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
    Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
    J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-delivery of p53 and MDM2 inhibitor RG7388 using a hydroxyl terminal PAMAM dendrimer derivative for synergistic cancer therapy.
    Chen K; Xin X; Qiu L; Li W; Guan G; Li G; Qiao M; Zhao X; Hu H; Chen D
    Acta Biomater; 2019 Dec; 100():118-131. PubMed ID: 31568878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
    Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
    Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
    Xu C; Liu H; Pirozzi CJ; Chen LH; Greer PK; Diplas BH; Zhang L; Waitkus MS; He Y; Yan H
    Acta Neuropathol Commun; 2021 Nov; 9(1):178. PubMed ID: 34732238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.
    Canon J; Osgood T; Olson SH; Saiki AY; Robertson R; Yu D; Eksterowicz J; Ye Q; Jin L; Chen A; Zhou J; Cordover D; Kaufman S; Kendall R; Oliner JD; Coxon A; Radinsky R
    Mol Cancer Ther; 2015 Mar; 14(3):649-58. PubMed ID: 25567130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment.
    Yee-Lin V; Pooi-Fong W; Soo-Beng AK
    Mini Rev Med Chem; 2018; 18(2):173-183. PubMed ID: 28714398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer targets and mechanisms of calycosin to treat nasopharyngeal carcinoma.
    Liu F; Pan Q; Wang L; Yi S; Liu P; Huang W
    Biofactors; 2020 Jul; 46(4):675-684. PubMed ID: 32449282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
    Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA
    Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells.
    Ciardullo C; Aptullahoglu E; Woodhouse L; Lin WY; Wallis JP; Marr H; Marshall S; Bown N; Willmore E; Lunec J
    Haematologica; 2019 Dec; 104(12):2429-2442. PubMed ID: 31004033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21
    Natarajan U; Venkatesan T; Radhakrishnan V; Samuel S; Rasappan P; Rathinavelu A
    Medicina (Kaunas); 2019 Jan; 55(2):. PubMed ID: 30700046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.
    Zanjirband M; Edmondson RJ; Lunec J
    Oncotarget; 2016 Jun; 7(26):40115-40134. PubMed ID: 27223080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ablation of Cancer Stem Cells by Therapeutic Inhibition of the MDM2-p53 Interaction in Mucoepidermoid Carcinoma.
    Andrews A; Warner K; Rodriguez-Ramirez C; Pearson AT; Nör F; Zhang Z; Kerk S; Kulkarni A; Helman JI; Brenner JC; Wicha MS; Wang S; Nör JE
    Clin Cancer Res; 2019 Mar; 25(5):1588-1600. PubMed ID: 30498096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma.
    Chen L; Rousseau RF; Middleton SA; Nichols GL; Newell DR; Lunec J; Tweddle DA
    Oncotarget; 2015 Apr; 6(12):10207-21. PubMed ID: 25844600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib.
    Berberich A; Kessler T; Thomé CM; Pusch S; Hielscher T; Sahm F; Oezen I; Schmitt LM; Ciprut S; Hucke N; Ruebmann P; Fischer M; Lemke D; Breckwoldt MO; von Deimling A; Bendszus M; Platten M; Wick W
    Clin Cancer Res; 2019 Jan; 25(1):253-265. PubMed ID: 30274984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SALL4 induces radioresistance in nasopharyngeal carcinoma via the ATM/Chk2/p53 pathway.
    Nie X; Guo E; Wu C; Liu D; Sun W; Zhang L; Long G; Mei Q; Wu K; Xiong H; Hu G
    Cancer Med; 2019 Apr; 8(4):1779-1792. PubMed ID: 30907073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An oral 2-hydroxypropyl-β-cyclodextrin-loaded spirooxindole-pyrrolizidine derivative restores p53 activity via targeting MDM2 and JNK1/2 in hepatocellular carcinoma.
    Gao X; Wei M; Shan W; Liu Q; Gao J; Liu Y; Zhu S; Yao H
    Pharmacol Res; 2019 Oct; 148():104400. PubMed ID: 31425749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
    Esfandiari A; Hawthorne TA; Nakjang S; Lunec J
    Mol Cancer Ther; 2016 Mar; 15(3):379-91. PubMed ID: 26832796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced cytotoxicity.
    Voon YL; Ahmad M; Wong PF; Husaini R; Ng WT; Leong CO; Lane DP; Khoo AS
    Oncol Rep; 2015 Oct; 34(4):1692-700. PubMed ID: 26252575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway.
    Xu J; Han M; Shen J; Guan Q; Bai Z; Lang B; Zhang H; Li Z; Zuo D; Zhang W; Wu Y
    Cancer Lett; 2016 Dec; 383(1):9-17. PubMed ID: 27693458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.